Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 391

Similar articles for PubMed (Select 16631912)

1.

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C.

Lancet. 2006 Apr 22;367(9519):1335-42.

PMID:
16631912
2.

Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.

Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L; Médecins Sans Frontieres.

AIDS. 2006 May 12;20(8):1163-9.

PMID:
16691068
3.
4.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

5.

Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.

Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, Samb B, Lackritz E.

Lancet. 2002 Jul 6;360(9326):34-40.

PMID:
12114039
6.

Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa.

Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, Tempelman HA.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):977-84. doi: 10.1007/s10096-008-0534-2. Epub 2008 Jul 16.

PMID:
18629557
7.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.

Lancet. 2004 Jul 3-9;364(9428):29-34.

PMID:
15234853
8.
9.
10.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
11.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

12.

Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda.

Weidle PJ, Wamai N, Solberg P, Liechty C, Sendagala S, Were W, Mermin J, Buchacz K, Behumbiize P, Ransom RL, Bunnell R.

Lancet. 2006 Nov 4;368(9547):1587-94.

PMID:
17084759
13.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

14.

Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.

Bourgeois A, Laurent C, Mougnutou R, Nkoué N, Lactuock B, Ciaffi L, Liégeois F, Andrieux-Meyer I, Zekeng L, Calmy A, Mpoudi-Ngolé E, Delaporte E.

Antivir Ther. 2005;10(2):335-41.

PMID:
15865228
15.

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.

Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, Castelnuovo B, Schaefer P, Spacek LA, Gasasira AF, Katabira E, Colebunders R, Quinn TC, Ronald A, Thomas DL, Kekitiinwa A; Academic Alliance for AIDS Care and Prevention in Africa.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):187-93.

PMID:
17693883
16.

Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.

Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy JF.

AIDS. 2007 Nov 12;21(17):2293-301.

PMID:
18090277
17.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.

18.

Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.

Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C.

AIDS Patient Care STDS. 2008 Apr;22(4):301-12. doi: 10.1089/apc.2007.0101.

PMID:
18338961
19.

Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.

20.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk